Printer Friendly

OCTREOSCAN 111 FROM IMCERA'S MALLINCKRODT MEDICAL UNIT RECOMMENDED FOR MARKETING BY FDA MEDICAL IMAGING DRUGS ADVISORY COMMITTEE

 NORTHBROOK, Ill., May 28 /PRNewswire/ -- IMCERA Group Inc. (NYSE: IMA) announced today that the U.S. Food and Drug Administration's (FDA) Medical Imaging Drugs Advisory Committee earlier today recommended the agency approve OctreoScan(TM) 111 (Kit for the preparation of Indium In-111 Pentetreotide), a product from IMCERA's Mallinckrodt Medical unit, for marketing in the U.S.
 OctreoScan is a radiopharmaceutical developed to image certain types of tumors.
 In October 1992 Mallinckrodt Medical submitted a New Drug Application for OctreoScan for use in gamma scintigraphy, including single photon emission computed tomography (SPECT), to detect and localize tumors that originate from neuroendocrine cells. These tumors are found in many parts of the body, primarily in the abdominal area.
 The agent is designed for use in the diagnosis of these types of cancer and to help physicians evaluate the spread of the disease. The results of an OctreoScan study may be useful in the determination of patient treatment.
 "OctreoScan employs a unique technology to locate and confirm the presence of neuroendocrine cell-based tumors," according to Peter C. Vermeeren, Mallinckrodt Medical group vice president, nuclear medicine. "Research suggests the agent may have broad implications in the early detection of these cancers."
 The OctreoScan kit combines Indium-111, an isotope with high density imaging qualities, with a modified version of the drug octreotide, introduced by Sandoz in 1988 under the name Sandostatin. Octreotide is an analogue of somatostatin, a peptide which naturally occurs in the body.
 Research at the University Hospital Dijkzigt in Rotterdam, The Netherlands, found that the radiolabeled octreotide derivative appears to bind to many tumor cells with somatostatin receptors. Studies have shown that up to 80 percent of neuroendocrine tumors have somatostatin receptors.
 The imaging agent was developed by Mallinckrodt Medical in conjunction with the University Hospital Dijkzigt and Sandoz Pharma Ltd. of Basel, Switzerland. OctreoScan has undergone human clinical trials in Europe, where approval is being sought. Mallinckrodt Medical also plans to apply for approval in Canada and Japan. The agent will be manufactured in St. Louis and Petten, The Netherlands.
 "This favorable recommendation moves OctreoScan a significant step forward in the FDA review process," said Robert G. Moussa, president and chief executive officer of Mallinckrodt Medical. "We hope to have OctreoScan on the market by the end of this year."
 Mallinckrodt Medical is a leading producer of radiopharmaceuticals in the $800 million worldwide nuclear medicine market, which is expected to grow to about $1.1 billion by 1995. Mallinckrodt also operates a network of nuclear medicine pharmacies in 30 key markets across the U.S. and Canada.
 With fiscal 1992 net sales of $620 million and operating earnings of $128 million, Mallinckrodt Medical is a major supplier of products for radiology, cardiology, nuclear medicine, anesthesiology and critical care. Its products are sold in more than 100 countries and are used by more than 7,000 health care facilities in the U.S.
 IMCERA, a Fortune 250 company with fiscal 1992 net sales of more than $1.7 billion, has two other international, technology-based businesses--Mallinckrodt Specialty Chemicals of Chesterfield, Mo., and Pitman-Moore of Mundelein, Ill.
 -0- 5/28/93
 /CONTACT: Dave Prichard of IMCERA Group Inc., 708-205-2270/
 (IMA)


CO: IMCERA Group Inc. ST: Illinois IN: MTC SU:

TS -- NY035 -- 3409 05/28/93 13:06 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 28, 1993
Words:544
Previous Article:ORLANDO UTILITIES COMMISSION $85.5 MILLION SUB BONDS RATED 'AA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:LL&E ROYALTY TRUST ANNOUNCES DISTRIBUTION
Topics:


Related Articles
FDA ADVISORY COMMITTEE ENDORSES MYOSCINT WOULD BE FIRST MAB-BASED IMAGING AGENT IN THE UNITED STATES
IMCERA'S MALLINCKRODT MEDICAL UNIT INTRODUCES ULTRAJECT PREFILLED SYRINGE IN GERMANY
MBI AND IMCERA'S MALLINCKRODT MEDICAL UNIT ANNOUNCE FILING OF NDS FOR ALBUNEX(R)
FDA ADVISORY PANEL RECOMMENDS APPROVAL FOR MBI'S ALBUNEX(R)
IMCERA'S MALLINCKRODT MEDICAL UNIT SUBMITS NEW DRUG APPLICATION TO FDA FOR CANCER IMAGING AGENT
IMCERA'S MALLINCKRODT MEDICAL UNIT AND SANDOZ PHARMA LTD. SIGN AGREEMENT TO SHARE MOLECULAR RESEARCH
MOLECULAR BIOSYSTEMS INC. SUBMITS PMA AMENDMENT TO FDA
OCTREOSCAN RELEASED FOR MARKETING IN UNITED STATES FOR IMAGING OF TUMORS AND METASTASES
OCTREOSCAN MEETS THE REQUIREMENTS FOR MARKETING AUTHORIZATION IN EUROPE FOR IMAGING OF TUMORS AND METASTASES
FDA Advisory Panel Recommends Clearance of ALBUNEX(R) Ultrasound Imaging Agent for Use in Diagnosing Fallopian Tube Patency

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters